title: Angioimmunoblastic T-cell lymphoma revealed after treatment of B-cell lymphoproliferative diseases.
authors.forename: Delphine
authors.initials: D
authors.lastname: Kerob
authors.forename: Bertrand
authors.initials: B
authors.lastname: Arnulf
authors.forename: Marie Dominique
authors.initials: MD
authors.lastname: Vignon-Pennamen
authors.forename: Lila Ben
authors.initials: LB
authors.lastname: M'Barek
authors.forename: Felix
authors.initials: F
authors.lastname: Agbalika
authors.forename: Michel
authors.initials: M
authors.lastname: Rybojad
authors.forename: Jean Michel
authors.initials: JM
authors.lastname: Cayuela
authors.forename: Josette
authors.initials: J
authors.lastname: Briere
authors.forename: Jean Paul
authors.initials: JP
authors.lastname: Fermand
authors.forename: Celeste
authors.initials: C
authors.lastname: Lebbe
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D001402:B-Lymphocytes; D005260:Female; D006801:Humans; D007119:Immunoblastic Lymphadenopathy / Q000139:chemically induced; D016399:Lymphoma, T-Cell / Q000139:chemically induced*; D008232:Lymphoproliferative Disorders / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D000069283:Rituximab
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab